|
1
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deschesnes RG, Huot J, Valerie K and
Landry J: Involvement of p38 in apoptosis-associated membrane
blebbing and nuclear condensation. Mol Biol Cell. 12:1569–1582.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pandey P, Raingeaud J, Kaneki M,
Weichselbaum R, Davis RJ, Kufe D and Kharbanda S: Activation of p38
mitogen-activated protein kinase by c-Abl-dependent and
-independent mechanisms. J Biol Chem. 271:23775–23779. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Winograd-Katz SE and Levitzki A: Cisplatin
induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF
receptor. Oncogene. 25:7381–7390. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/Akt and apoptosis: Size matters. Oncogene.
22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kandel ES and Hay N: The regulation and
activities of the multifunctional serine/threonine kinase Akt/PKB.
Exp Cell Res. 253:210–229. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang M, Liu ZM, Li XC, Yao YT and Yin ZX:
Activation of ERK1/2 and Akt is associated with cisplatin
resistance in human lung cancer cells. J Chemother. 25:162–169.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chi C, He ZF, Liu Y, Lin XM and Sun CC:
Expression and clinical significance of circadian gene Per2 in
non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 35:129–131.
2013.(In Chinese). PubMed/NCBI
|
|
9
|
Liu B, Xu K, Jiang Y and Li X: Aberrant
expression of Per1, Per2 and Per3 and their prognostic relevance in
non-small cell lung cancer. Int J Clin Exp Pathol. 7:7863–7871.
2014.PubMed/NCBI
|
|
10
|
Okabe T, Kumagai M, Nakajima Y, Shirotake
S, Kodaira K, Oyama M, Ueno M and Ikeda M: The impact of HIF1α on
the Per2 circadian rhythm in renal cancer cell lines. PLoS One.
9:e1096932014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao H, Zeng ZL, Yang J, Jin Y, Qiu MZ, Hu
XY, Han J, Liu KY, Liao JW, Xu RH and Zou QF: Prognostic relevance
of Period1 (Per1) and Period2 (Per2) expression in human gastric
cancer. Int J Clin Exp Pathol. 7:619–630. 2014.PubMed/NCBI
|
|
12
|
Esposito L, Conti D, Ailavajhala R, Khalil
N and Giordano A: Lung Cancer: Are we up to the Challenge? Curr
Genomics. 11:513–518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu L and Lee CC: The circadian clock:
Pacemaker and tumour suppressor. Nat Rev Cancer. 3:350–361. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang X, He X, Yang Z and Jabbari E:
Mammalian PER2 regulates AKT activation and DNA damage response.
Biochem Cell Biol. 90:675–682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ
and Chang JG: Deregulated expression of the PER1, PER2 and PER3
genes in breast cancers. Carcinogenesis. 26:1241–1246. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sjöblom T, Jones S, Wood LD, Parsons DW,
Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al:
The consensus coding sequences of human breast and colorectal
cancers. Science. 314:268–274. 2006. View Article : Google Scholar : PubMed/NCBI
|
